home / stock / biov:cc / biov:cc news

BIOV:CC News and Press, Biovaxys Technology Corp. From 01/08/26

Stock Information
Company Name: Biovaxys Technology Corp.
Stock Symbol: BIOV:CC
Market: CNQC
Website: biovaxys.com
Menu
BIOV:CC BIOV:CC Quote BIOV:CC Short BIOV:CC News BIOV:CC Articles BIOV:CC Message Board
Get BIOV:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
BIOV:CC - BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other im...
BIOV:CC - 2025 Corporate Review

(TheNewswire) VANCOUVER, BC, December 31 st . 2025 / - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of operating initiatives over the past year following the integration of the DPX™ platform i...

BIOV:CC - Phase 1 Results Drive New Attention to Breast Cancer Play

2025-12-17 10:03:00 ET Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outc...

BIOV:CC - BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other i...
BIOV:CC - BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D

(TheNewswire) VANCOUVER, BC, December 15, 2025/ – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF ) ("BioVaxys" or "Company") is pleased to announce that Marianne Stanford, PhD, has joined BioVaxys as Scientific Advisor.   Dr Stanford was V...

BIOV:CC - BioVaxys Technology Corp. Closes Debt Settlement Transaction

(TheNewswire) VANCOUVER, BC, November 25, 2025 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“ BioVaxys ” or the “ Company ”) announces that, further to its news release dated November 14, 2025, it has issued 1,7...

BIOV:CC - BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement

2025-11-19 10:02:35 ET VANCOUVER, BC, November 19, 2025 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company”) announces that it has closed its previously announced non-brokered private placement financing (the “Offering&#x...
BIOV:CC - BioVaxys Technology Corp. Announces Debt Settlement Transaction

2025-11-14 09:34:42 ET VANCOUVER, BC, November 13, 2025 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company”) announces that it has entered into debt settlement agreements with certain creditors of the Company (the ȁ...

BIOV:CC - CSE Bulletin: MOC Eligibility Update

Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - The following CSE-Listed symbol will become MOC Eligible as detailed below.   The full list of MOC-Eligible symbols is available at https://thecse.com/trading/trading-resources/#market-on-close . For further information, p...

BIOV:CC - BioVaxys Announces Extension of Life Offering Closing Date

VANCOUVER, British Columbia, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“ BioVaxys ” or the “ Company ”) announces an extension of its non-brokered private placement financing (the “ Offering ”) previou...
Previous 10 Next 10